Clinical Trial Update: Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis [Phase 1]

View source ↗

Summary

This Phase 1 study reports safety and tolerability data for REGN668 (SAR231893) given in sequential ascending doses to patients with atopic dermatitis; the tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• REGN668 (SAR231893)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Dermatitis | Phase 1 | Status: COMPLETED